GSK plc (LSE/NYSE: GSK) and Empirico Inc. (Empirico), a clinical-stage biotechnology company with leading capabilities in human genetics-driven target discovery and siRNA medicines, today announced that they have entered into a worldwide…
GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases
